Key Takeaways Cidara shares have jumped 217.8% in 2025 so far on progress with its influenza drug candidate CD388.The phase IIb NAVIGATE study met all primary and secondary endpoints across multiple dose levels.The phase III ANCHOR study began ahead of schedule and could support regulatory filing if successful.Shares of Cidara Therapeutics (CDTX) have skyrocketed 217.8% in the year so far, driven by positive updates from the development program of its only clinical-stage pipeline candidate, CD388, for the p ...